drugset / Trial / NCT03514017
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
Phase 2
Terminated
5 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Janssen Scientific Affairs, LLC · collabMerck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the impact of sequential overlapping treatment with PD-1 monoclonal antibody (mAb), pembrolizumab/MK-1375, followed by ibrutinib on endogenous immune function in previously untreated, high-risk CLL patients. Immune function will be evaluated through various laboratory correlative tests.
Timeline
- Start
- 2019-05-31
- Primary completion
- 2023-05-16
- Completion
- 2023-05-16
Outcome
Outcome not reported
Stopped (Business): “Funding unavailable”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrutinib | Small molecule | 420 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |